ClinicalTrials.gg
RecruitingNCT07080931Updated Mar 5, 2026

Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

A Phase 3 interventional study of 5% minoxidil foam and Placebo for 5% Minoxidil Foam in Androgenetic Alopecia, sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. (part of 3SBio Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Feb 2025, registered Jul 2025).
  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
294
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies in Alopecia with a site in China — 12 open to participants now, 14 under way, 4 of them phase 3. Alopecia · China.

Planned enrollment
7th of 32
294 · median 128
Started
2025
with 7 others
Phase 3
5 of 33
2 open now
Primary completion
2027-12
later than 11 of 13 live
Registered
24th of 33
by date

Among the 33 studies in Alopecia with a site in China, this one is the 7th largest by planned enrollment of the 32 interventional ones that give a count, is one of 8 that started in 2025, is one of 5 in phase 3, reaches primary completion later than 11 of the 13 other live ones, and was the 24th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

12 of the 33 studies in Alopecia with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 74 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 46 (62%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Alopecia with a site in China, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

Keywords

  • Androgenetic Alopecia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participate in the study and be able to provide a written Form (ICF);
  • Female aged ≥ 18 years;
  • Investigator-diagnosed androgenetic alopecia;
  • Hair loss severity graded D3 to D6 on the Savin scale;
  • Willingness to maintain identical hairstyle, hair color, and hair length at each follow-up visit;
  • No pregnancy plans during the study and for 3 months post-last dose, with commitment to highly effective . Women of must have negative serum pregnancy test ≤7 days prior to first product administration

Exclusion criteria

Exclusion Criteria:

  • Trial participants with known to minoxidil or any of the product.
  • Trial participants with known hair loss disorders other than androgenetic alopecia (AGA)
  • Trial participants with any scalp disorder at screening that may interfere with efficacy evaluation, as determined by the investigator.
  • Lactating women
  • Trial participants with history of hypotension or uncontrolled hypertension
  • Trial participants with abnormal laboratory findings at screening that may compromise efficacy and safety assessments, as determined by the investigator.
  • Trial participants with clinically significant abnormalities at screening
  • Trial participants with history of prior to screening.
  • Trial participants known to have conditions or disorders that may affect hair growth or compromise study results.
  • Trial participants with history of using systemically administered therapeutic drugs prior to screening that may interfere with efficacy evaluation, etc.
  • Trial participants with history of topical minoxidil application to alopecia-affected areas prior to screening.
  • Trial participants with no response to prior minoxidil treatment for alopecia
  • Trial participants with history of 5α-reductase inhibitor use prior to screening.
  • Trial participants with history of spironolactone or cyproterone treatment prior to screening.
  • Trial participants with history of autologous -rich plasma (PRP) administration prior to screening.
  • Trial participants with history of chemotherapy, cytotoxic agents, scalp radiation, and/or low-level laser therapy (LLLT) or surgical scalp procedures for FAGA prior to screening.
  • Trial participants with history of using medical shampoos or solutions containing ingredients or other components that may interfere with efficacy evaluation prior to screening.
  • Trial participants planning hair transplantation during the study period, or using hair weaving, non-breathable wigs, or hair bonding during treatment.
  • Trial participants in other interventional clinical trials within 3 months before screening (excluding non-interventional studies and screen failures) , or planned concurrent clinical trial enrollment.
  • Trial participants with history of major surgery within 3 months before screening or planning major surgery during the study period.
  • Trial participants deemed by the investigator to have other conditions that may compromise compliance or render them unsuitable for the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
294 participants (estimated)

Study arms

  • Experimental
    5% Minoxidil Foam

    Drug: 5% minoxidil foam

  • Placebo comparator
    Placebo for 5% Minoxidil Foam

    Drug: Placebo for 5% Minoxidil Foam

Interventions

  • Drug5% minoxidil foam

    Trial participants applied 5% minoxidil foam topically once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.

  • DrugPlacebo for 5% Minoxidil Foam

    Trial participants applied placebo once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Target Area Hair Count (TAHC) at Week 24, assessed via digital phototrichogram analysis in trial participa

    Time frame: Week 24

Secondary outcomes

  1. Mean change from baseline in Target Area Hair Count (TAHC) at Weeks 6, 12, and 18

    Time frame: Weeks 6, 12, and 18

  2. Percent change from baseline in Target Area Hair Count (TAHC) at Weeks 12 and 24

    Time frame: Weeks 12 , 24

  3. Self-assessed satisfaction scores at Weeks 6, 12, 18, and 24

    Time frame: Weeks 6, 12, 18, 24

07

Study locations

1 of 1 sites recruiting
  • Beijing, China
    Beijing, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.

Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2025
First posted
Jul 23, 2025
StartActual
Feb 24, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07080931
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Feb 24, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion